オーラノフィン市場：形態別、適応症別-2024-2030年の世界予測

オーラノフィン市場規模は2023年に2億920万米ドルと推定され、2024年には2億1,899万米ドルに達し、CAGR 4.81%で2030年には2億9,085万米ドルに達すると予測されます。

オーラノフィンは金含有経口投与化合物で、疾患修飾性抗リウマチ薬（DMARD）に分類されます。関節の炎症と痛みを特徴とする慢性的な自己免疫疾患である関節リウマチの治療薬として開発されました。オーラノフィンは、免疫系を調節して炎症を抑え、病気の進行を遅らせます。さらに、その免疫調節特性は、他の自己免疫疾患やある種のがんに対する潜在的な有効性の研究に拍車をかけています。一方、その治療効果にもかかわらず、その使用はしばしば腎障害や肝障害などの潜在的な副作用と慎重に比較検討されるため、治療中の患者を定期的にモニタリングする必要があります。オーラノフィンは、自己免疫疾患を管理するためのユニークなアプローチであり、慢性疾患管理における有効性と安全性のバランスの重要性を強調しています。関節リウマチの有病率の上昇と、薬剤耐性が高まる中での代替治療の必要性が、基本的な促進要因となっています。特定のがんや寄生虫に対するオーラノフィンの有効性を実証する調査の進歩は、市場をさらに拡大します。さらに、慢性疾患やがん研究のための政府・非政府の資金援助は、市場拡大に重要な役割を果たしています。しかし、オーラノフィンに関連する胃腸障害や皮膚科的反応などの副作用は、一部の患者の間でその受容性を制限しています。規制上のハードルや、新規用途の臨床試験にかかる高コストも大きな課題です。オーラノフィンの腫瘍学と寄生虫学への応用の探求は、大きな成長機会をもたらします。薬剤耐性がんや寄生虫に対する有効性が期待されることから、新たな市場分野が開拓される可能性があります。さらに、オーラノフィンの用途拡大を目指した製薬会社と研究機関の提携は、さらなる成長も促すでしょう。

形態：オーラノフィンカプセルは、均一な分布が確保され、活性薬剤を全身にデリバリーするのに適しています。

カプセルのオーラノフィンは、主に関節リウマチ管理のために設計された経口治療の選択肢として認められています。カプセルの利便性は、他の剤形の投薬が困難な患者に適しています。オーラノフィンカプセルは、全身へのドラッグデリバリーを可能にし、全身への均一な分布を保証します。オーラノフィンカプセルは、炎症抑制、関節可動域の改善、疼痛軽減に効果があり、患者のコンプライアンスと治療効果に最適化された投与量と投与スケジュールで、特に注目されています。オーラノフィンの錠剤は、関節リウマチの治療において、使いやすさと正確な投与量管理を両立させ、オーダーメイドのアプローチを提供します。錠剤は、携帯性、安定性、そしてオーラノフィンの薬物動態学的プロファイルを改善する放出制御製剤を組み込むことができる点で、非常に好まれています。これは、長期にわたって体内の薬物レベルがより一定であることを意味し、患者の転帰の改善や副作用の軽減につながる可能性があります。また、錠剤は、慢性疾患の長期管理において重要な要素である治療スケジュールの遵守を促進することができます。

適応症：炎症に関与する細胞メカニズムのため、血清反応陽性RAの管理にはオーラノフィンが優先されます。

血清反応陰性関節リウマチ（RA）とは、関節リウマチ患者において一般的に認められるリウマトイド因子（RF）抗体や抗環状シトルリン化ペプチド（抗CCP）抗体を患者の血液中に含まない関節リウマチのサブタイプを指します。これらの抗体がないにもかかわらず、血清陰性RAは重大な関節の炎症と損傷を引き起こす可能性があります。経口金化合物であるオーラノフィンは、抗炎症作用があるため、血清陰性RAの治療に使用されています。オーラノフィンは免疫系を調節することにより、炎症と病気の進行を抑えます。血清反応陰性RAにおけるオーラノフィンを用いた治療アプローチは、症状のコントロールと関節障害の予防に重点を置いており、特異的なバイオマーカーがないため、このサブタイプの診断と管理に課題があることを認識しています。血清陽性関節リウマチは、患者の血液中にリウマトイド因子（RF）抗体および/または抗環状シトルリン化ペプチド（抗CCP）抗体が存在することを特徴とします。この型のRAは、より重大な関節障害や関節外症状を発症する高いリスクなど、より侵攻的な疾患経過を伴うことが多いです。オーラノフィンは、炎症に関与する細胞メカニズムを阻害することができるため、血清陽性のRAを管理する上でその役割が認められています。炎症性サイトカインの産生につながる特定の経路を標的とすることにより、オーラノフィンは罹患関節の炎症、腫脹、疼痛を軽減するのに役立ちます。オーラノフィンは、RAの第一選択薬ではありませんが、従来の疾患修飾性抗リウマチ薬（DMARDs）や生物学的製剤に不耐性または無反応の患者に対する治療選択肢の一つであり、血清反応陽性RA患者の疾患活動性を低下させ、生活の質を改善することを目的としています。

地域別インサイト

南北アメリカ、特に米国とカナダでは、オーラノフィンの市場は慢性関節リウマチの治療における長期使用によって牽引されています。同市場は成熟しており、安定した需要がありますが、その主な理由は、確立されたヘルスケア・インフラと同薬の処方を支持する償還政策にあります。しかし、新規の生物学的製剤であるDMARDsやバイオシミラーとの競合が激化しており、市場シェアの課題となっています。欧州では、費用対効果や臨床成績が重視され、市場規制が厳しいため、有効性は証明されているものの、オーラノフィンの成長性が制限される可能性があります。中東は市場規模こそ小さいものの、ヘルスケア・インフラと投資の拡大により有望視されています。アジア太平洋地域は、急速に発展するヘルスケアシステム、患者の意識の高まり、関節リウマチの有病率の増加により、オーラノフィン市場の大きな成長が見込まれています。膨大な人口を抱え、医療環境が改善されている中国やインドなどの国々は、市場に大きく貢献すると予想されます。さらに、この地域では研究開発活動が活発化しているため、新たな治療用途への応用が期待されます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはオーラノフィン市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、オーラノフィン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.オーラノフィン市場の市場規模および予測は？

2.オーラノフィン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.オーラノフィン市場の技術動向と規制枠組みは？

4.オーラノフィン市場における主要ベンダーの市場シェアは？

5.オーラノフィン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 関節リウマチの罹患率の上昇と代替治療の必要性
    • オーラノフィンは寄生虫感染症、特定のがん、および抗ウイルス剤に対する潜在的効果がある
    • 慢性疾患およびがん調査に対する政府および非政府による資金提供
  • 抑制要因
    • オーラノフィンに関連する副作用
  • 機会
    • 新たな治療用途におけるオーラノフィンの有効性の探究
    • 製薬企業と調査機関の提携
  • 課題
    • 複雑な規制状況と臨床試験の高コスト
• 市場セグメンテーション分析
  • 形態：有効薬剤を全身に送達し、均一な分布を保証するオーラノフィンカプセルの適合性
  • 適応症：炎症に関与する細胞メカニズムのため、血清陽性RAの管理にはオーラノフィンが優先される
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 オーラノフィン市場：形態別

• カプセル
• タブレット

第7章 オーラノフィン市場：適応症別

• 血清陰性関節リウマチ
• 血清陽性関節リウマチ

第8章 南北アメリカのオーラノフィン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のオーラノフィン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのオーラノフィン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析（2023年）
• FPNVポジショニングマトリックス（2023年）
• 競合シナリオ分析
  • 関節炎財団、難治性関節リウマチ調査に110万米ドルを投資
• 戦略分析と提言

第12章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. AURANOFIN MARKET RESEARCH PROCESS
• FIGURE 2. AURANOFIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. AURANOFIN MARKET DYNAMICS
• FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 20. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL AURANOFIN MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 20. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 21. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 22. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 23. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 24. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 25. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 26. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 27. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 28. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 29. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 30. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 31. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 32. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 33. CANADA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 34. CANADA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 35. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 36. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 37. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 38. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 39. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 40. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 41. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 42. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 43. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 44. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 45. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 46. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 48. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 50. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 52. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 53. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 54. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 55. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 56. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 57. CHINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 58. CHINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 59. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 60. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 61. INDIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 62. INDIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 63. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 64. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 65. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 66. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 67. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 68. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 69. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 70. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 71. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 72. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 73. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 74. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 75. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 76. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 77. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 78. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 79. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 80. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 81. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 82. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 83. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 84. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 86. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 88. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 89. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 90. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 91. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 92. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 93. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 94. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 95. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 96. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 97. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 98. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 99. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 107. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 108. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 109. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 110. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 111. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 112. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 113. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 114. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 115. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 116. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 117. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 118. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 119. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 120. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 121. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 122. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 123. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 124. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 125. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 126. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 127. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 128. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 129. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 130. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 131. ITALY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 132. ITALY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 133. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 134. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 135. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 136. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 137. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 138. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 139. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 140. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 141. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 142. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 143. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 144. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 145. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 146. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 147. POLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 148. POLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 149. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 150. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 151. QATAR AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 152. QATAR AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 153. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 154. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 155. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 156. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 157. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 158. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 160. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 162. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 164. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 166. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 167. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 168. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 169. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 170. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 171. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 172. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 173. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 174. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 175. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 176. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 177. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 178. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 179. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 180. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 181. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 182. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
• TABLE 188. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 190. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 191. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023

[191 Pages Report] The Auranofin Market size was estimated at USD 209.20 million in 2023 and expected to reach USD 218.99 million in 2024, at a CAGR 4.81% to reach USD 290.85 million by 2030.

Auranofin is a gold-containing, orally administered compound classified as a disease-modifying antirheumatic drug (DMARD). It was specifically designed for the treatment of rheumatoid arthritis, a chronic autoimmune situation characterized by inflammation and pain in the joints. Auranofin works by modulating the immune system to decrease inflammation and slows the progression of the disease. Additionally, its immunoregulatory properties have spurred research into its potential efficacy against other autoimmune disorders and certain types of cancer. Despite its therapeutic benefits, its use is often carefully weighed against potential side effects, including renal and hepatic impairment, necessitating regular monitoring of patients under treatment. Auranofin represents a unique approach to managing autoimmune diseases, emphasizing the importance of balancing efficacy with safety in chronic disease management. The rising prevalence of rheumatoid arthritis and the need for alternative treatments amidst growing drug resistance are fundamental growth drivers. Advances in research demonstrating auranofin's efficacy against certain cancers and parasites further expand its market. Moreover, governmental and non-governmental funding for chronic diseases and cancer research plays a significant role in market expansion. However, side effects associated with auranofin, such as gastrointestinal issues and dermatological reactions, limit its acceptability among some patients. Regulatory hurdles and the high cost of clinical trials for new applications are significant challenges. The exploration of Auranofin's application in oncology and parasitology presents significant growth opportunities. Its potential effectiveness against drug-resistant cancers and parasites could open new market segments. Additionally, partnerships between pharmaceutical companies and research institutions aimed at expanding Auranofin's applications could spur further growth.

Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution

Auranofin in capsule form is a recognized oral treatment option primarily designed for the management of rheumatoid arthritis. The convenience of capsule administration makes it suitable for patients who may have difficulty with other forms of medication. Auranofin capsules provide a systemic delivery of the active drug, ensuring a uniform distribution throughout the body. This form is particularly noted for its effectiveness in reducing inflammation, improving joint mobility, and decreasing pain with a dosage and administration schedule that is optimized for patient compliance and therapeutic efficacy. The tablet form of auranofin offers a tailored approach to the treatment of rheumatoid arthritis, combining ease of use with precise dosage control. Tablets are highly favored for their portability, stability, and ability to incorporate controlled-release formulations, which can improve the pharmacokinetic profile of auranofin. This means a more consistent drug level in the body over time, potentially leading to improved patient outcomes and reduced side effects. The tablet form can also facilitate adherence to treatment schedules, an important factor in the long-term management of chronic conditions.

Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.

Seronegative rheumatoid arthritis (RA) refers to a subtype of rheumatoid arthritis where the blood of the patient does not contain rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies, which are typically found in rheumatoid arthritis patients. Despite the absence of these antibodies, seronegative RA can still cause significant joint inflammation and damage. Auranofin, an oral gold compound, has been utilized in the management of seronegative RA for its anti-inflammatory properties. It functions by modulating the immune system, thus reducing the inflammation and progression of the disease. Treatment approaches with auranofin in seronegative RA emphasize controlling symptoms and preventing joint damage, acknowledging the challenges in diagnosing and managing this subtype due to the lack of specific biomarkers. Seropositive Rheumatoid Arthritis is characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies in the patient's blood. This form of RA is often associated with a more aggressive disease course, including more significant joint damage and a higher risk of developing extra-articular manifestations. Auranofin's role in managing seropositive RA has been recognized due to its capacity to inhibit cellular mechanisms involved in inflammation. By targeting specific pathways that lead to the production of pro-inflammatory cytokines, auranofin helps in reducing inflammation, swelling, and pain in affected joints. Although it is not among the first-line treatments for RA, Auranofin presents a therapeutic option for patients intolerant or unresponsive to conventional disease-modifying antirheumatic drugs (DMARDs) or biologic agents, aiming to reduce disease activity & improve the quality of life of patients with seropositive RA.

Regional Insights

In the Americas, particularly in the United States and Canada, the market for auranofin has been driven by its prolonged use in treating chronic rheumatoid arthritis. The market is mature with a stable demand, largely due to the established healthcare infrastructure and reimbursement policies favoring the drug's prescription. However, growing competition from newer biologic DMARDs and biosimilars poses challenges to its market share. In Europe, the market is highly regulated with a strong emphasis on cost-effectiveness and clinical outcomes, which could limit the growth potential of Auranofin despite its proven efficacy. The Middle East, while smaller in market size, shows promise due to growing healthcare infrastructure and investment. The Asia Pacific region is anticipated to depict significant growth for the auranofin market due to rapidly evolving healthcare systems, increasing patient awareness, and growing prevalence of rheumatoid arthritis. Countries including China and India, with their vast populations and improving healthcare settings, are expected to contribute substantially to the market. Furthermore, the region's increasing research and development activities may offer new opportunities for Auranofin in alternative therapeutic applications.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Auranofin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Auranofin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Auranofin Market, highlighting leading vendors and their innovative profiles. These include Chugai Pharmaceutical Co Ltd, LGM Pharma, Prometheus Laboratories Inc., Sebela Pharmaceuticals Inc., Taj Pharmaceuticals Limited, and Xediton Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Auranofin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Form
  • Capsule
  • Tablet

• Indication
  • Seronegative Rheumatoid Arthritis
  • Seropositive Rheumatoid Arthritis

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Auranofin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Auranofin Market?

3. What are the technology trends and regulatory frameworks in the Auranofin Market?

4. What is the market share of the leading vendors in the Auranofin Market?

5. Which modes and strategic moves are suitable for entering the Auranofin Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of rheumatoid arthritis and the need for alternative treatments
    • 5.1.1.2. Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
    • 5.1.1.3. Governmental and non-governmental funding for chronic diseases and cancer research
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with Auranofin
  • 5.1.3. Opportunities
    • 5.1.3.1. Exploring auranofin's efficacy in new therapeutic applications
    • 5.1.3.2. Partnerships between pharmaceutical companies and research institutions
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory landscape and the high cost of clinical trials
• 5.2. Market Segmentation Analysis
  • 5.2.1. Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
  • 5.2.2. Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Auranofin Market, by Form

• 6.1. Introduction
• 6.2. Capsule
• 6.3. Tablet

7. Auranofin Market, by Indication

• 7.1. Introduction
• 7.2. Seronegative Rheumatoid Arthritis
• 7.3. Seropositive Rheumatoid Arthritis

8. Americas Auranofin Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Auranofin Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Auranofin Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research
• 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

• 12.1. Key Company Profiles
• 12.2. Key Product Portfolio